2.46
price up icon2.87%   0.02
 
loading
前日終値:
$2.44
開ける:
$2.59
24時間の取引高:
88,620
Relative Volume:
1.11
時価総額:
$3.70M
収益:
-
当期純損益:
$-12.30M
株価収益率:
-0.3825
EPS:
-6.4313
ネットキャッシュフロー:
$-11.13M
1週間 パフォーマンス:
-4.20%
1か月 パフォーマンス:
-35.81%
6か月 パフォーマンス:
-53.60%
1年 パフォーマンス:
-71.64%
1日の値動き範囲:
Value
$2.35
$2.6999
1週間の範囲:
Value
$2.3308
$2.89
52週間の値動き範囲:
Value
$2.18
$22.35

Palisade Bio Inc Stock (PALI) Company Profile

Name
名前
Palisade Bio Inc
Name
セクター
Healthcare (1195)
Name
電話
(858) 704-4900
Name
住所
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Name
職員
9
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
PALI's Discussions on Twitter

PALI を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
PALI 2.5198 3.70M 0 -12.30M -11.13M -6.4313
VRTX 450.34 115.43B 10.63B -479.80M -1.35B 13.33
REGN 746.04 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 591.88 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 245.32 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.38 24.89B 3.30B -501.07M 1.03B 11.54

Palisade Bio Inc (PALI) 最新ニュース

pulisher
08:16 AM

Palisade Bio to Present Preclinical Results for PALI-2108 - GlobeNewswire

08:16 AM
pulisher
Nov 14, 2024

ARMISTICE CAPITAL, LLC Acquires Shares in Palisade Bio Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit - The Manila Times

Nov 14, 2024
pulisher
Nov 13, 2024

Contrasting Palisade Bio (NASDAQ:PALI) & Anavex Life Sciences (NASDAQ:AVXL) - Defense World

Nov 13, 2024
pulisher
Nov 12, 2024

Palisade Bio Inc (PALI) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 12, 2024

Palisade Bio Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Palisade Bio Advances UC Drug Trial: Key Phase 1 Milestones & Patent Wins Boost Pipeline | PALI Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 07, 2024

Palisade Bio initiates phase 1 study of new UC drug - Investing.com

Nov 07, 2024
pulisher
Nov 07, 2024

Palisade Bio initiates phase 1 study of new UC drug By Investing.com - Investing.com Australia

Nov 07, 2024
pulisher
Nov 07, 2024

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Palisade Bio Announces First Subject Dosed in Phase 1 - GlobeNewswire

Nov 07, 2024
pulisher
Nov 07, 2024

Palisade Bio Launches Phase 1 Trial for Novel Ulcerative Colitis Drug PALI-2108 | PALI Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 04, 2024

Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World

Nov 04, 2024
pulisher
Oct 31, 2024

Palisade Bio advances novel IBD treatment PALI-2108 - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Palisade Bio advances novel IBD treatment PALI-2108 By Investing.com - Investing.com UK

Oct 31, 2024
pulisher
Oct 31, 2024

HYCU® Recognized as CRN 2024 Product of the Year Finalist - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

Palisade Bio Announces Positive Data from Two Ex Vivo - GlobeNewswire

Oct 31, 2024
pulisher
Oct 31, 2024

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan

Oct 31, 2024
pulisher
Oct 30, 2024

PALI stock touches 52-week low at $3.09 amid market fluctuations - Investing.com

Oct 30, 2024
pulisher
Oct 24, 2024

Alto Neuroscience’s depression drug trial fails at phase 2 - BioPharma-Reporter.com

Oct 24, 2024
pulisher
Oct 24, 2024

Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - MedCity News

Oct 24, 2024
pulisher
Oct 15, 2024

Palisade Bio Announces Abstract Accepted for Presentation - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting - The Manila Times

Oct 15, 2024
pulisher
Oct 12, 2024

Sutro Biopharma (NASDAQ:STRO) & Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast - Defense World

Oct 12, 2024
pulisher
Oct 12, 2024

Meta Platforms (NASDAQ:META) Shares Up 0.6% Following Analyst Upgrade - Defense World

Oct 12, 2024
pulisher
Oct 11, 2024

Palisade Bio receives Health Canada nod for UC drug trial By Investing.com - Investing.com Australia

Oct 11, 2024
pulisher
Oct 10, 2024

Palisade Bio receives Health Canada nod for UC drug trial - Investing.com

Oct 10, 2024
pulisher
Oct 10, 2024

Palisade Bio Cleared by Health Canada to Commence Phase 1 - GlobeNewswire

Oct 10, 2024
pulisher
Oct 10, 2024

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) - Yahoo Finance

Oct 10, 2024
pulisher
Oct 08, 2024

Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - The Manila Times

Oct 08, 2024
pulisher
Oct 04, 2024

Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews

Oct 04, 2024
pulisher
Sep 28, 2024

Palisade Bio, Inc. (NASDAQ:PALI) Shares Sold by Armistice Capital LLC - Defense World

Sep 28, 2024
pulisher
Sep 28, 2024

Palisade Bio inks new deal with CEO Finley; terms disclosed By Investing.com - Investing.com Canada

Sep 28, 2024
pulisher
Sep 28, 2024

Palisade Bio inks new deal with CEO Finley; terms disclosed - Investing.com India

Sep 28, 2024
pulisher
Sep 27, 2024

Palisade Bio CEO Finley’s Revised Employment and Compensation Deal - TipRanks

Sep 27, 2024
pulisher
Sep 26, 2024

Palisade submits CTA for PDE4 inhibitor prodrug for ulcerative colitis - BioWorld Online

Sep 26, 2024
pulisher
Sep 25, 2024

PALI stock touches 52-week low at $3.3 amid market fluctuations - Investing.com UK

Sep 25, 2024
pulisher
Sep 25, 2024

PALIPalisade Bio, Inc. Latest Stock News & Market Updates - StockTitan

Sep 25, 2024
pulisher
Sep 25, 2024

Palisade Bio Provides Update on Progress Toward Launch of - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan

Sep 25, 2024
pulisher
Sep 24, 2024

Klea Holding Evaluates Generous Takeover Offer - TipRanks

Sep 24, 2024
pulisher
Sep 23, 2024

The growth track for Kura Oncology Inc (KURA) has changed recently - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Potential Price Increase for Kulicke & Soffa Industries, Inc. (KLIC) After Recent Insider Activity - Knox Daily

Sep 23, 2024
pulisher
Sep 22, 2024

Big Changes At Disney Animation: Jennifer Lee Steps Down And Jared Bush Steps In - mxdwn.com

Sep 22, 2024
pulisher
Sep 22, 2024

116,268 Shares in Proficient Auto Logistics, Inc. (NASDAQ:PAL) Purchased by First Eagle Investment Management LLC - MarketBeat

Sep 22, 2024
pulisher
Sep 21, 2024

Angelina Jolie overwhelmed by ‘beautiful feeling’ of motherhood - FemaleFirst

Sep 21, 2024
pulisher
Sep 20, 2024

Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga

Sep 20, 2024
pulisher
Sep 20, 2024

Palisade Bio (NASDAQ:PALI) Stock Quotes, Forecast and News Summary - Benzinga

Sep 20, 2024
pulisher
Sep 20, 2024

Proficient Auto Logistics (NASDAQ:PAL) Earns "Outperform" Rating from Barrington Research - MarketBeat

Sep 20, 2024
pulisher
Sep 19, 2024

Jared Bush Taking Over Jennifer Lee’s Role As Walt Disney Animation Studios Chief Creative Officer - What's On Disney Plus

Sep 19, 2024

Palisade Bio Inc (PALI) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Palisade Bio Inc (PALI) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Williams Donald Allen
Director
Jun 11 '24
Option Exercise
0.00
340
0
340
Jones Mitchell Lawrence
Chief Medical Officer
May 28 '24
Option Exercise
0.00
4,290
0
4,313
Finley John David
CEO, CFO, Director
May 28 '24
Option Exercise
0.00
7,068
0
14,079
Williams Donald Allen
Director
May 28 '24
Buy
4.86
1,000
4,863
1,000
Finley John David
CEO, CFO, Director
May 24 '24
Buy
4.81
1,000
4,810
8,437
Jones Mitchell Lawrence
CEO, CFO, Director
May 06 '24
Option Exercise
0.00
460
0
880
Finley John David
CEO, CFO, Director
May 06 '24
Option Exercise
0.00
443
0
6,832
Finley John David
CEO, CFO, Director
Mar 11 '24
Option Exercise
0.00
5,558
0
96,849
Neal James R
Director
Feb 09 '24
Option Exercise
0.00
10,920
0
10,920
Csimma Cristina
Director
Feb 08 '24
Option Exercise
0.00
12,800
0
12,862
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):